CD30 CAR-expressing Autologous T Lymphocytes in Treating Patients with Recurrent or Refractory CD30+ Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Inclusion Criteria

• PROCUREMENT INCLUSION CRITERIA: Diagnosis of recurrent CD30+ HL or CD30+ NHL, or newly diagnosed patients unable to receive or complete standard therapy OR diagnosis of relapsed/refractory CD30+ HL or CD30+ NHL with a treatment plan that will include high dose therapy and stem cell transplantation
• PROCUREMENT INCLUSION CRITERIA: CD30 positive tumor (result can be pending at this time)
• PROCUREMENT INCLUSION CRITERIA: Hemoglobin (Hgb) > 8.0
• PROCUREMENT INCLUSION CRITERIA: Informed consent explained to, understood by and signed by patient/guardian; patient/guardian given copy of informed consent
• PROCUREMENT INCLUSION CRITERIA: Karnofsky or Lansky score of > 60%
• TREATMENT INCLUSION CRITERIA:
• Diagnosis - CD30+ HL or CD30+ NHL: * During the dose escalation phase: only adult patients with active disease failing standard therapy * After dose escalation: any patient (children or adults) newly diagnosed, unable to receive or complete standard therapy OR diagnosis of relapsed/refractory CD30+ HL or CD30+ NHL with a treatment plan that will include high dose therapy and autologous stem cell transplantation
• CD30 positive tumor
• Bilirubin 1.5 times or less than the upper limit of normal
• Aspartate aminotransferase (AST) 3 times or less than the upper limit of normal
• Serum creatinine 1.5 times or less than upper limit of normal
• Pulse oximetry of > 90% on room air
• Karnofsky or Lansky score of > 60%
• Available autologous T cells with >= 15% expression of CD30CAR determined by flow-cytometry
• Recovered from acute toxic effects of all prior chemotherapy at least one week and 30 days from prior chemotherapy before entering this study
• Adequate pulmonary function with forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobin
• Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condom
• Patients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects; patients or their guardians will be given a copy of the consent form

Exclusion Criteria

• PROCUREMENT EXCLUSION CRITERIA:
• Active infection with human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) (can be pending at this time)
• TREATMENT EXCLUSION CRITERIA:
• Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks
• Received anti-CD30 antibody-based therapy within the previous 4 weeks
• History of hypersensitivity reactions to murine protein-containing products
• Pregnant or lactating
• Tumor in a location where enlargement could cause airway obstruction
• Current use of systemic corticosteroids